Focused on CRISPR-based therapies for rare diseases and oncology, this biotech just reported a notable insider sale in public ...
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...
Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation in vivo CRISPR gene editing ...
Zebrafish (Danio Rerio) have emerged as a powerful bioengineering platform for next-generation drug discovery, offering an unparalleled combination of ...
Morning Overview on MSN
New CRISPR leap could transform treatment for genetic diseases
Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of ...
AZoLifeSciences on MSN
CRISPR for Christmas? The year’s biggest gene editing breakthroughs, unwrapped
In 2025, CRISPR advanced gene editing with safe, effective therapies and AI tools, marking a shift towards real-world ...
CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its its gene-editing therapy's slow rollout. But its development partner, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback